Thermo Fisher Scientific Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $11.99B | $11.01B | $12.22B | $11.12B | $10.86B | $10.36B | $11.40B | $10.60B |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $364.0M | $336.0M | $357.0M | $346.0M | $352.0M | $342.0M | $374.0M | $346.0M |
| SG&A Expense | $2.33B | $2.18B | $2.35B | $2.16B | $2.14B | $2.08B | $2.20B | $2.10B |
| Operating Income | $2.09B | $1.86B | $2.26B | $1.94B | $1.83B | $1.72B | $2.02B | $1.84B |
| Operating Margin | 17.4% | 16.9% | 18.5% | 17.5% | 16.9% | 16.6% | 17.7% | 17.3% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | $1.92B | $1.73B | $2.15B | $1.83B | $1.71B | $1.62B | $1.94B | $1.74B |
| Income Tax Expense | $167.0M | $70.0M | $153.0M | $207.0M | $92.0M | $95.0M | $149.0M | $99.0M |
| Net Income | $1.74B | $1.65B | $1.96B | $1.62B | $1.62B | $1.51B | $1.83B | $1.63B |
| Net Margin | 14.5% | 15.0% | 16.1% | 14.5% | 14.9% | 14.5% | 16.0% | 15.4% |
| EPS (Basic) | $4.68 | $4.44 | $5.22 | $4.28 | $4.28 | $3.99 | $4.80 | $4.26 |
| EPS (Diluted) | $4.68 | $4.43 | $5.21 | $4.27 | $4.28 | $3.98 | $4.78 | $4.25 |
| Shares Outstanding (Basic) | 371.0M | 372.0M | 377.0M | 378.0M | 378.0M | 378.0M | 382.0M | 382.0M |
| Shares Outstanding (Diluted) | 371.0M | 373.0M | 378.0M | 378.0M | 378.0M | 379.0M | 383.0M | 384.0M |
| Dividends Per Share | $0.47 | $0.47 | $0.43 | $0.43 | $0.43 | $0.43 | $0.39 | $0.39 |